We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity.
- Authors
Zebertavage, Lauren; Bambina, Shelly; Shugart, Jessica; Alice, Alejandro; Zens, Kyra D.; Lauer, Peter; Hanson, Bill; Gough, Michael J.; Crittenden, Marka R.; Bahjat, Keith S.
- Abstract
Dysregulated signaling via the epidermal growth factor receptor (EGFR)-family is believed to contribute to the progression of a diverse array of cancers. The most common variant of EGFR is EGFRvIII, which results from a consistent and tumor-specific in-frame deletion of exons 2–7 of the EGFR gene. This deletion generates a novel glycine at the junction and leads to constitutive ligand-independent activity. This junction forms a novel shared tumor neo-antigen with demonstrated immunogenicity in both mice and humans. A 21-amino acid peptide spanning the junctional region was selected, and then one or five copies of this 21-AA neo-peptide were incorporated into live-attenuated Listeria monocytogenes-based vaccine vector. These vaccine candidates demonstrated efficient secretion of the recombinant protein and potent induction of EGFRvIII-specific CD8+ T cells, which prevented growth of an EGFRvIII-expressing squamous cell carcinoma. These data demonstrate the potency of a novel cancer-specific vaccine candidate that can elicit EGFRvIII-specific cellular immunity, for the purpose of targeting EGFRvIII positive cancers that are resistant to conventional therapies.
- Subjects
CANCER vaccines; EPIDERMAL growth factor receptors; CD8 antigen; T cells; ANTINEOPLASTIC agents
- Publication
PLoS ONE, 2019, Vol 14, Issue 01, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0209153